TheraNym Biologics Private Limited, a subsidiary of Aurobindo Pharma, has announced an expansion of its existing contract manufacturing operations (CMO) agreement with Merck Sharpe & Dohme Singapore Trading Pte. Ltd. (MSD). The expansion involves the execution of an additional product schedule, which will see the construction of a new large-scale mammalian drug substance manufacturing facility.
The new facility, referred to as ‘Unit 2’, will be a greenfield project featuring mammalian cell culture bioreactors with a total capacity of 60,000 litres. This facility will also include the necessary downstream purification infrastructure to produce drug substances. The investment for this project is estimated to be between USD 150 million and USD 175 million.
This expansion aims to build upon the existing relationship between TheraNym and MSD, which was first established in May 2024. The agreement is set to further the scope of TheraNym’s contract manufacturing operations for biologicals, enhancing its production capabilities on both domestic and international fronts.
The terms of the agreement specify that TheraNym will be responsible for building the manufacturing facility, manufacturing the products, and supplying them to MSD. The agreement does not involve any related party transactions, and the promoter group of Aurobindo Pharma does not have any interest in the entity being acquired.
The rationale behind this investment is to expand the existing contract manufacturing operations for biologicals, thereby strengthening TheraNym’s position in the market and enhancing its production capacity.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).